Trichostatin A induces 5-lipoxygenase promoter activity and mRNA expression via inhibition of histone deacetylase 2 and 3 by Pufahl, Laura et al.
Trichostatin A induces 5-lipoxygenase promoter 
activity and mRNA expression via inhibition 
of histone deacetylase 2 and 3
Laura Pufahl 
a, #, Careen Katryniok 
a, #, Nicole Schnur 
a, Bernd L. Sorg 
a, 
Julia Metzner 
a, Manuel Grez 
b, Dieter Steinhilber 
a, *
a Institute of Pharmaceutical Chemistry/ZAFES, Goethe University Frankfurt, Frankfurt, Germany
b Georg-Speyer-Haus, Frankfurt, Germany
Received: March 8, 2011; Accepted: August 4, 2011
Abstract
The 5-lipoxygenase (5-LO) is the key enzyme in the formation of leukotrienes. We have previously shown that the histone deacetylase
(HDAC) inhibitor trichostatin A (TSA) activates 5-LO transcription via recruitment of Sp1, Sp3 and RNA polymerase II to the proximal 
promoter. To identify the HDACs involved in the regulation of 5-LO promoter activity isoform-specific HDAC inhibitors were applied. 5-LO
promoter activity and mRNA expression were up-regulated by the class I HDAC inhibitors apicidin and MS-275 but not by class II
inhibitors. Knockdown of HDAC 1, 2 and 3 revealed that HDAC2 and HDAC3 but not HDAC1 is involved in the up-regulation of 5-LO mRNA
expression. To analyse the chromatin modifications at the 5-LO promoter associated with HDAC inhibition, the time course of 5-LO mRNA
induction by trichostatin A was investigated and the concomitant changes in histone modifications at the 5-LO promoter in HL-60, U937
and Mono Mac6 cells were determined. Chromatin immunoprecipitation analysis revealed that trichostatin A increases acetylation of his-
tones H3 and H4 at the 5-LO core promoter in HL-60 and U937 cells whereas no significant changes were observed in Mono Mac6 cells.
The appearance of H3 and H4 acetylation preceded the 5-LO mRNA induction whereas in all three cell lines, induction of 5-LO mRNA
expression correlated with histone H3 lysine 4 trimethylation (H3K4me3), a marker for transcriptional activity of gene promoters.
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Introduction
The human 5-LO catalyses the formation of leukotrienes, which
represent mediators of inflammation and allergy. The 5-LO path-
way is involved in innate immune responses but also associated
with diseases such as atherosclerosis, asthma and certain types of
cancer. 5-LO expression is mainly restricted to B-lymphocytes and
cells of myeloid origin such as granulocytes, monocytes, mast
cells and dendritic cells [1, 2]. The 5-LO promoter possesses a
unique GC-rich region which contains consensus sequences for
the transcription factors Sp1 and Egr-1 (GC-boxes) and which are
important for basal transcriptional activity [3]. The promoter
region contains eight GC-boxes, but lacks TATA and CAAT boxes.
As such, it resembles promoters of typical housekeeping genes,
which is in contrast to the cell type specific expression of the gene.
In studies with 5-LO positive (HL-60, Mono Mac6) and 5-LO neg-
ative myeloid cell lines (U937), it was found that DNA methylation
strongly down-regulates 5-LO promoter activity [4]. In myeloid
cells, 5-LO expression and activity is strongly up-regulated during
cell differentiation by calcitriol and transforming growth factor-
(TGF-) [5]. We found that these effects are promoter-independent
and are due to stimulation of 5-LO transcript elongation and 
maturation [6]. In contrast to these observations, induction of 
5-LO mRNA expression by the HDAC inhibitor TSA is mainly due to
5-LO promoter activation [7]. Induction of 5-LO promoter activity
by TSA correlates with the recruitment of the transcription factors
Sp1 and Sp3 to the 5-LO core promoter and depends on an Sp1
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binding site close to the transcription start site [8]. Histone
deacetylase enzymes deacetylate histones as well as other pro-
teins such as transcription factors and are divided into different
classes, namely class I (comprising HDACs 1,2,3,8), class II 
(4,5,6,7,9,10) and class IV (11) [9].
Inhibition of classes I and II HDACs by TSA leads to profound
changes in the acetylation status of histones and other proteins
such as transcription factors involved in the regulation of gene
transcription. Histone acetylation is the most prominent epigenetic
marker for active transcription and the level of histone acetylation
usually correlates with the transcriptional activity of genes [10].
Histone acetylation is catalysed by histone acetyl transferases
(HATs), which promote gene activation. Histone deacetylases
induce repression of gene expression by the reduction of histone
acetylation and the dynamic interaction of HATs and HDACs deter-
mines the transcriptional activity.
In addition to acetylation, methylation of histones at certain
amino acid residues also contributes to the so-called histone code
that is linked to the regulation of gene expression. Histone H3
lysine 4 trimethylation (H3K4me3) represents an important
marker for transcriptional activity in fully active promoters,
whereas H3K4me2 is linked to basal transcription [3, 11]. H3K4
methylation is catalysed by MLL family of proteins [12]. Histone
H3 lysine 9 monomethylation (H3K9me) is considered to mark
transcriptional repression [13].
To identify the HDAC subtype that is involved in 5-LO gene acti-
vation, subtype-specific HDAC inhibitors were used and knock-
down experiments were performed. Both approaches revealed that
up-regulation of 5-LO promoter activity and mRNA expression by
HDAC inhibitors is due to inhibition of HDAC2 and HDAC3. To
analyse the changes in chromatin markers in the 5-LO promoter,
histone H3 and H4 acetylation (acH3, acH4) and H3 lysine 4
trimethylation (H3K4me3) was determined at the 5-LO promoter
after HDAC inhibition. An increase in the acetylation status of the
core histone proteins H3 and H4 was found by chromatin
immunoprecipitation (ChIP) assays in TSA-treated HL-60 and U937
but not in Mono Mac6 cells. This change in histone acetylation
preceded the induction of 5-LO mRNA. In all three investigated 
cell lines the presence of H3K4me3, a marker for transcriptional
activity, correlated with the induction of 5-LO mRNA suggesting
that the recruitment of the MLL complex is a critical event in the
up-regulation of 5-LO promoter activity.
Materials and methods
Cells and culture
HL-60 cells (DSMZ, ACC 3) and U937 cells (DSMZ, ACC 5) were grown at
37C with 6% CO2 in RPMI 1640 medium  10% (v/v) foetal calf serum
(FCS), penicillin (100 U/ml), streptomycin (100 g/ml). Mono Mac6 cells
(DSMZ, ACC 124) were grown in RPMI 1640 medium supplemented with
10% (v/v) FCS, 1 non-essential amino acids, sodium pyruvate (1 mM),
oxalacetate (1 mM), insulin (10 g/ml), penicillin (100 U/ml) and strepto-
mycin (100 g/ml). HeLa cells were grown in DMEM supplemented with
10% (v/v) FCS, penicillin (100 U/ml) and streptomycin (100 g/ml).
Reagents
Trichostatin A (#T8552; Sigma-Aldrich, Taufkirchen, Germany) and cyclo-
heximide (#239763, CHX; Calbiochem, Darmstadt, Germany) were dis-
solved in ethanol 96%. apicidin (A8851; Sigma-Aldrich), MS-275 
(ALX-270-378; Axxora, Lörrach) and SB-379278A (CAS# 167897-35-0;
Best West Laboratories, Salt Lake City, USA) were dissolved in DMSO. 
MC-1568 was kindly provided by Prof. Antonello Mai, Rome, and dissolved
in methanol.
RNA extraction and cDNA synthesis
Two micrograms of total RNA were extracted from U937, HL-60 or Mono Mac6
cells by the Total RNA Mini Kit from Omega, Darmstadt; (R6834-02). RNA was
reverse transcribed into cDNA using the iScript cDNA synthesis kit (170-8897;
Biorad, Munich, Germany) according to the manufacturer’s protocol.
Real-time PCR analysis for detection 
of time-dependent induction of 5-LO 
mRNA expression
Quantitative PCR analysis was performed with a MyiQ cycler (Biorad). The
sequences of the 5-LO primers were 5-GTTCCTGAATGGCTGCAAC (for-
ward) and 5- GGCAATGGGGACAATCTTG (reverse). Results were normal-
ized to riboprotein P0 Ct values. Sequences of the riboprotein P0 primers
were as follows: 5-AGATGCAGCAGATCCGCAT (forward) and 5-GTGGT-
GATACCTAAAGCCTG (reverse). Each sample was set up in triplicates. The
expression was quantified by comparative Ct method.
Determination 5-LO mRNA expression in the
HDAC knockdown cell lines
Quantitative PCR analysis of the knockdown cells was performed with a
StepOne PCR system (Applied Biosystems, Darmstadt, Germany). The 
5-LO primer pair is described earlier. Quantitative results for 5-LO mRNA
levels were obtained using a 5-LO expression plasmid (pcDNA-5LO).
These results were related to absolute -actin mRNA levels that were
obtained using a plasmid (pcDNA-actin). -Actin primer sequences were:
5-CGGGACCTGACTGACTACCTC (forward) and 5-CTTCTCCTTATTGT-
CACGCACG (reverse). Similarly, samples were quantified in triplicates.
Western blot analysis of HDAC knockdowns 
in mono Mac6 cells
For detection of the knockdown efficiency of HDACs, cell pellets (610
6
cells) were lysed by ultrasonification (3  15 sec.). The samples were
mixed with the same volume of 2 SDS-PAGE loading buffer, heated for 
5 min. at 95C and analysed for HDAC proteins by SDS-PAGE and Western
blotting using the following antibodies: HDAC1 (sc-7872, dilution 1:200;J. Cell. Mol. Med. Vol 16, No 7, 2012
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Santa Cruz Biotechnology, Heidelberg, Germany), HDAC2 (sc-7899, dilu-
tion 1:200; Santa Cruz Biotechnology), HDAC3 (sc-11417, dilution 1:200;
Santa Cruz Biotechnology) and -actin (sc-1616, dilution 1:1000; Santa
Cruz Biotechnology). For detection, the Odyssey
® imaging   system was
used (LI-COR; Bioscience, Bad Homburg, Germany).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays were performed as described pre-
viously with some modifications [8]. Cells were incubated with 330 nM
TSA for the indicated times before harvest. The collected immune com-
plexes were washed twice with RIPA buffer (10 mM Tris-HCl pH 8.1, 1%
Triton-X, 0.1% SDS, 0.25% sodium deoxycholate) and equilibrated with TE
buffer (10 mM Tris-HCl pH8, 1 mM EDTA pH 8) before harvest. The anti-
bodies used for immunoprecipitation were anti-acetyl-histone H3 (06-599;
Upstate, Millipore Schwalbach), anti-acetyl-histone H4 (Upstate 06-866),
anti-histone H3-K4 trimethyl (Upstate 07-473), anti-histone H3-K9
monomethyl (Upstate 07-450) and normal rabbit IgG (Santa Cruz
Biotechnology, Sc-2027). The DNA was analysed by PCR (32 cycles) using
the following primers: 5-AGGAACAGACACCTCGCTGAGGAG (forward) and
5-GAGGCTGAGGTAGATGTAGTCGTCAGTG (reverse), which cover the 5-LO
promoter from bp 	286 to 78. PCR was visualized after separation on
1% agarose gels containing 0.5% ethidium bromide with the Gel Doc 1000
System (Biorad, Munich, Germany).
Calcium phosphate transfection and reporter gene
assay
Twenty-four hours prior to transfection, HeLa cells were seeded at a 
density of 4  10
4 cells per well. 0.8 g 5-LO luciferase reporter gene
plasmid pN10 [7] which comprises 831 bp of the 5-LO promoter and 
0.2 g pCMVRenilla as internal standard were transfected using the cal-
cium phosphate method. After 24 hrs, cells were assayed for reporter gene
activity with the Dual-Glo™   Stop and Glow Luciferase Assay system follow-
ing the manufacturer’s protocol (Promega, Mannheim, Germany) and
measured with a Tecan infinite
® M200 reader. Renilla luciferase activity
was used to   normalize the luciferase activity to the transfection efficacy.
Data are shown as relative light units.
shRNA knockdown of HDAC1, HDAC2 and HDAC3
For gene knockdown a lentiviral shRNA approach was used. MISSION
shRNA plasmids for HDAC1 (NM_004965; TRCN 0000195103), HDAC2
(NM_001527; TRCN0000196590) and HDAC3 (NM_003883; TRCN
0000196925) were obtained from Sigma-Aldrich.
Generation of the lentiviral particles was performed in HEK293T cells. A
total of 4  10
4 HEK293T cells per well were seeded in a 24-well plate in 
1 ml complete DMEM medium. After 24 hrs, cells were transfected by   calcium
phosphate transfection. The DNA transfection mixtures contained 10 g of
the shRNA plasmid and 10 g packaging plasmids (VSVG). After 4 hrs, the
medium was changed and cells were cultured for 72 hrs. The supernatants
containing the infectious lentiviral particles were filtered using a 0.22 m
  filter. For transduction the Mono Mac6 cells were seeded at a concentration
of 0.4  10
6/ml and supplemented with protamine   sulfate (4 g/ml). 
Ten microlitres of each viral supernatant were added to 500 l of cell
  suspension and centrifuged (2500 r.p.m., 90 min., 32C). The transduced
cells were grown in complete medium for 2 days before puromycin 
(0.75 g/ml final concentration) was added to select transduced clones.
After 3 weeks, knockdown efficiency was analysed by Western blot.
Statistics
Statistic evaluation of the data was performed by ANOVA, *P 
 0.05, **P 

0.01 and ***P 
 0.001.3.
Results
Only class I HDAC inhibitors induce 
5-LO promoter activity
To identify the HDACs which are involved in the transcriptional
regulation of 5-LO, more specific HDAC inhibitors than TSA were
tested for induction of 5-LO promoter activity using reporter gene
assays [7]. MS-275 that preferentially inhibits HDAC1 but also
affects HDAC2 and HDAC3 at micromolar concentrations, apicidin
as HDAC2 and HDAC3 inhibitor, SB-379278A as HDAC8 inhibitor
and MC-1568 as inhibitor of class IIa HDACs were tested (Table 1).
Apicidin strongly increased 5-LO promoter activity at a concentra-
tion of 100 nM, which was almost comparable to TSA (330 nM).
Table 1 EC50-values of selected HDAC inhibitors for 5-LO promoter
activation as determined by reporter gene assays and comparison
with IC50-values reported for specific HDAC isoforms
Compound
5-LO promotor
activation (EC50)
HDAC inhibition reported 
in the literature
Apicidin 64 nM 10 M (HDAC1) [38]
20 nM (HDAC2) [38]
43 nM (HDAC3) [38]
MS-275 539 nM 181 nM (HDAC1) [38, 39]
300 nM (HDAC1) [40]
180 nM (HDAC1) [41]
1.1 M (HDAC2) [38, 39]
2.3 M (HDAC3) [38, 39]
8 M (HDAC3) [40]
0.74 M (HDAC3) [41]
SB-379278A 1 M 500 nM (HDAC8) [40]
MC-1568 1 M 220 nM (HDACs class IIa) [42]1464 © 2011 The Authors
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In addition, MS-275 that inhibits HDAC1–HDAC3 activated the 
5-LO promoter at 1 M. The EC50-values for induction of 5-LO
promoter activity are given in Table 1. Of note, no 5-LO promoter
activation was detectable with the compounds SB-379278A and
MC-1568 (Fig. 1A).
Interestingly, similar results were obtained when the effects of
these HDAC inhibitors on 5-LO mRNA expression were investi-
gated in Mono Mac6 cells using quantitative RT-PCR. The cells
were incubated with the HDAC inhibitors for 24 hrs at the indicated
concentrations. Trichostatin A (330 nM) increased 5-LO mRNA
Fig. 1 Up-regulation of 5-LO promoter activity (A)
and 5-LO mRNA expression (B) by histone deacety-
lase inhibitors. (A) 5-LO promoter activity was
determined by reporter gene assays. HeLa cells
were transfected with the 5-LO promoter construct
pN10 (comprises bp –844 to –12 in relation to ATG)
and cultured in the presence of the indicated HDAC
inhibitors for 24 hrs. Then, reporter gene activity
was determined. Results are expressed as relative
light units (RLU) of the internal standard plasmid
pCMVRenilla and are shown as mean  S.E. (n 
3). (B) Real-time PCR analysis of 5-LO mRNA
expression in Mono Mac6 cells. Cells were treated
with the indicated HDAC inhibitors for 24 hrs. Then,
the cells were harvested, RNA was isolated, reverse
transcribed into cDNA and 5-LO mRNA expression
was determined by real-time PCR. Values are given
as the mean  S.E. of three independent experi-
ments.J. Cell. Mol. Med. Vol 16, No 7, 2012
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expression in Mono Mac6 cells at about 62-fold. Apicidin (300
nM) led to an up to 50-fold induction of 5-LO mRNA, MS-275
increased 5-LO mRNA about 12-fold at a concentration of 1 M.
Neither SB-379278A (1 M) nor MC-1568 (1 M) showed a
strong  effect on 5-LO mRNA expression (Fig. 1B).
Taken together, the data show that the HDAC2 and HDAC3
inhibitor apicidin as well as to a lower extent the HDAC1–HDAC3
inhibitor MS-275 can mimic the TSA effects on 5-LO mRNA
expression and promoter activity.
Knockdown of class I histone deacetylases 
in Mono Mac6 cells
To further elucidate which class I HDAC isoenzyme is involved in
the regulation of 5-LO transcription, HDAC1, HDAC2 and HDAC3
expression was knocked down by shRNA. Mono Mac6 cells were
stably transfected using lentiviral shRNA constructs. The effi-
ciency of the knockdown was tested by Western blot analysis 
(Fig. 2B). The cell lines showed a strongly reduced protein expres-
sion of each HDAC that was targeted by the respective shRNA. 
5-LO mRNA expression in the HDAC knockdown cell lines was
determined by real-time PCR. Knockdown of HDAC2 as well as
HDAC3 led to a strong induction of 5-LO mRNA expression,
whereas the HDAC1 knockdown cell lines showed no up-regula-
tion but a slight down-regulation of 5-LO expression (Fig. 2A). The
data suggest that HDAC2 and HDAC3 are mainly involved in the
up-regulation of 5-LO mRNA expression by HDAC inhibitors.
Effects of HDAC inhibitors on 5-LO mRNA 
expression in Mono Mac6 cells after HDAC 
knockdown
To further verify the contribution of the HDAC1–HDAC3 isoforms
to 5-LO mRNA induction, the HDAC inhibitors TSA, apicidin and
MS-275 where added to each Mono Mac6 HDAC knockdown cell
line. As shown in Figure 3, 5-LO mRNA expression is low in
Fig. 2 Effects of HDAC 1, 2 and 3
knockdown on 5-LO mRNA expres-
sion in Mono Mac6 cells. (A) 5-LO
mRNA expression in Mono Mac6
cells and the respective Mono
Mac6 HDAC knockdown cell lines
was determined by quantitative
real-time PCR. Results are given as
5-LO mRNA copy number per 10
6
-actin mRNA copies. Data are
shown as mean  S.E. of six inde-
pendent experiments. (B) Western
blot analysis of HDAC expression in
the respective HDAC knockdown
cell lines. A total of 6  10
6 cells
were harvested and analysed by
Western blot for the indicated
HDAC isoform.1466 © 2011 The Authors
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HDAC1 knockdown cells and TSA and apicidin strongly induced 
5-LO mRNA expression (67- and 25-fold, respectively), whereas the
HDAC1 inhibitor MS-275 is without effect. In the HDAC2 and HDAC3
knockdown cell lines, the induction of 5-LO mRNA expression by
TSA is modest (1.5- and 3.5-fold) compared to 62-fold in the wild-
type cells (Fig. 2A) suggesting that there might be some additive
effect when HDACs are inhibited by TSA in the HDAC2 knockdown
cell line (Fig. 3B) or when HDAC2 is inhibited in the HDAC3 knock-
down cells by apicidin (Fig. 3C). Taken together, knockdown of
either HDAC2 or HDAC3 alone is sufficient for the strong up-regula-
tion of 5-LO expression (compare Fig. 2A) and additional HDAC
inhibition leads to an only modest 5-LO mRNA induction.
Induction of 5-LO mRNA expression by HDAC 
inhibition in HL-60 and U937 cells
To check whether HDAC inhibition induces 5-LO mRNA expression
in other myeloid cell lines than Mono Mac6, we analysed 5-LO
mRNA expression in HL-60 and U937 by quantitative RT-PCR.
Cells were grown in the presence or absence of TSA (330 nM) for
24 hrs. Compared to Mono Mac6 cells, a lower increase in 5-LO
mRNA expression was found in response to TSA treatment (about
four- to fivefold) in HL-60 and U937 cells. The results suggest that
induction of 5-LO mRNA expression by HDAC inhibitors is not
restricted to Mono Mac6 cells but seems to occur in myeloid cells
in general.
Time course of 5-LO mRNA induction 
by HDAC inhibition
To characterize the induction of 5-LO mRNA and the concomitant
changes in histone modifications, the time course of up-regulation
of 5-LO mRNA expression by HDAC inhibition was investigated
and correlated with histone acetylation at the 5-LO promoter.
Mono Mac6, HL-60 and U937 cells were incubated with TSA (330
nM) for the indicated times. Then, the cells were harvested and 5-
LO mRNA was determined by quantitative RT-PCR. In Mono Mac6
and HL-60 cells, a marked increase in 5-LO mRNA expression was
detected after 4 hrs, whereas in U937 cells the increase seems to
start immediately after treatment (Fig. 4). In U937 cells, maximal
5-LO expression was obtained after 24 hrs of TSA treatment
whereas in Mono Mac6 and HL-60 cells 5-LO mRNA expression
peaked at 16 hrs and declined again at 24 hrs. To distinguish
between primary or secondary effects which would require protein
synthesis, Mono Mac6 cells were treated with TSA in the presence
of the protein biosynthesis inhibitor CHX at 50 M. CHX did not
significantly affect induction of 5-LO mRNA expression by TSA up
to 4 hrs but at later time-points it partially inhibited the TSA effect
on 5-LO mRNA expression. This suggests that primary effects as
well as secondary effects at later time-points requiring protein
biosynthesis are involved in the up-regulation of 5-LO mRNA
expression by TSA (Fig. 4).
Fig. 3 Effects of HDAC inhibitors (TSA, apicidin and MS-275) on 5-LO
mRNA expression in HDAC1, HDAC2 and HDAC3 knockdown cell lines of
Mono Mac6. HDAC1 (A), HDAC2 (B) and HDAC3 (C) knockdown cells were
treated for 24 hrs with the indicated HDAC inhibitors at the indicated con-
centrations. Then, 5-LO mRNA expression in the respective Mono Mac6
HDAC knockdown cell lines was determined by quantitative real-time PCR.
Results are given as 5-LO mRNA copy number per 10
6 -actin mRNA
copies. Data are shown as mean  S.E. of three independent experiments.J. Cell. Mol. Med. Vol 16, No 7, 2012
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Basal and TSA-induced H3 and H4 acetylation 
at the 5-LO promoter
Histone deacetylase inhibitors are known to increase the global
histone acetylation status of many mammalian cells [14]. Here, we
analysed the time-dependent changes in the acetylation status of
histone proteins H3 and H4 during HDAC inhibition at the 5-LO
promoter by ChIP assays. Under basal conditions (w/o TSA),
Mono Mac6 cells showed higher levels of acetylated H3 and H4
proteins at the 5-LO core promoter compared to HL-60 and U937
cells (Fig. 5A). The lowest acetylation status of histone H3 and H4
at the 5-LO core promoter was observed in U937 cells where the
promoter is methylated (Fig. 5A). To study the time course of the
TSA effect on H3 and H4 acetylation, cells were incubated with
TSA for the indicated times before harvest (Fig. 5B). An increase
in acetylated histone proteins H3 and H4 was detectable in HL-60
and U937 cells (Fig. 5B). In U937 cells, maximal acetylation of his-
tone H3 and H4 was detectable after 1–8 hrs and 8 hrs of TSA
Fig. 4 Time course of 5-LO mRNA induction by TSA in Mono Mac6, HL-60
and U937 cells. The cells were cultured in the presence of TSA (330 nM)
with or without CHX (50 M) for the indicated times. Then, the cells were
harvested and RNA was isolated, reverse transcribed into cDNA and
analysed by quantitative real-time PCR for 5-LO mRNA expression. Data
are shown as mean 
 S.E. from three independent experiments.
Fig. 5 Chromatin immunoprecipitation assay (ChIP) for acetylated histones
H3 (acH3) and H4 (acH4) at the 5-LO core promoter in U937, HL-60 and
Mono Mac6 cells. Normal rabbit IgG antibodies served as negative control
to detect unspecific binding to histone proteins and the no antibody con-
trol (no ab) was used to detect unspecific binding to the immunoprecipita-
tion beads. The input sample (sheared chromatin without immunoprecipi-
tation) served as positive control for the PCR reaction. (A) Analysis of the
acetylation status of the histone proteins H3 and H4 at the 5-LO promoter
in U937, HL-60 and Mono Mac6 cells. 32 PCR cycles were applied. (B)
Time course of H3 and H4 acetylation of the 5-LO promoter in the indicated
cell lines. Cells were treated with TSA (330 nM) for the indicated times.
Then, the cells were harvested and analysed by ChIP as described. Thirty-
two PCR cycles were performed except for AcH4 in Mono Mac6 cells,
where the cycle number was reduced to 28.1468 © 2011 The Authors
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Fig. 5 Continued.J. Cell. Mol. Med. Vol 16, No 7, 2012
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Fig. 6 Chromatin immunoprecipitation assay for histone H3K4 trimethylation (H3K4me3) and histone H3K9 monomethylation (H3K9me) at the 5-LO core
promoter in Mono Mac6, HL-60 and U937 cells. Cells were grown with TSA (330 nM) for the indicated times. Then, the cells were harvested and sub-
jected to ChIP analysis. Thirty-two PCR cycles were applied.1470 © 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
incubation, respectively. In HL-60 cells, the highest histone H3
and H4 acetylation was observed after 16 and 8 hrs, respectively.
Interestingly, strong increases in H3 acetylation already occurred
in U937 and HL-60 cells 1 and 4 hrs after TSA addition which
clearly preceded the induction of 5-LO mRNA (Fig. 4). In contrast,
no significant changes in the H3 and H4 acetylation status were
detectable in Mono Mac6 cells, a fact that was already reported for
acetylated H4, but not for acetylated H3 [8].
HDAC inhibition induces histone H3 lysine 
4 trimethylation at the 5-LO promoter
H3K4me3 is classified as a marker for transcriptionally active pro-
moters, whereas H3K9me is a marker for transcriptional repres-
sion. Usually, the level of H3K4me3 correlates with the acetylation
status of histone H3 [15]. To elucidate whether TSA-induced 5-LO
expression correlates with H3 methylation, ChIP assays were per-
formed to determine H3K9me and H3K4me3 levels after incuba-
tion of the cells with TSA for the indicated times. An increase in
H3K4me3 levels was detectable in all three tested cell lines with a
maximum reached after 16–24 hrs of TSA treatment (Fig. 6).
H3K9me was only detectable in untreated U937 cells.
Effect of HDAC knockdown on histone acetylation
and methylation at the 5-LO promoter
In accordance to our results in wild-type Mono Mac6 cells where
HDAC inhibition did not change acH3 and acH4, TSA did not
increase acH3 and acH4 in the HDAC knockdown cell lines (Fig. 7).
An increase in H3K4me3 by TSA is clearly detectable in HDAC1
and HDAC2 knockdown cells. Interestingly, knockdown of HDAC3
leads to a very prominent H3K4 trimethylation, which corresponds
to the very high expression of 5-LO mRNA in this cell line.
Discussion
High expression of 5-LO mRNA and protein is mainly restricted to
myeloid cells such as mature granulocytes, monocytes and den-
dritic cells [2]. This tight regulation of 5-LO expression reflects the
function of 5-LO as key enzyme in the formation of leukotrienes,
which are mediators of inflammatory and host defence reactions
[16]. We found that the unspecific HDAC inhibitor TSA induces 
5-LO mRNA and protein expression in the human monocytic cell
line Mono Mac6 which is obviously due to the up-regulation of 
5-LO promoter activity as we could show with reporter gene
assays in HeLa cells [7]. Trichostatin A is a reversible HDAC
inhibitor of HDACs class I and class II. HeLa cells are known to
express HDAC1 [17], HDAC2 [18], HDAC3 [19] and HDAC8 [20]
from the HDAC class I group and at least HDAC4 and HDAC7 of
class IIa [21, 22] which suggests that one of these isoenzymes
Fig. 7 Chromatin immunoprecipitation assay for histone acetylation (acH3,
acH4), H3K4 trimethylation (H3K4me3) and histone H3K9 monomethyla-
tion (H3K9me) at the 5-LO core promoter in Mono Mac6 knockdown cell
lines. Cells were grown with or without TSA (330 nM) for 24 hrs. Then, the
cells were harvested and subjected to ChIP analysis. Thirty-two PCR cycles
were applied.J. Cell. Mol. Med. Vol 16, No 7, 2012
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could be responsible for the induction of 5-LO promoter activity
observed with reporter gene assays in HeLa cells by TSA. Previous
studies have demonstrated that HDAC inhibition by TSA leads to
the recruitment of Sp1 to an Sp1 binding site in close proximity to
the 5-LO transcription start site as well as accumulation of RNA
polymerase II [8]. This is in line with enhanced transcription initi-
ation. To get more insight into the regulation of the 5-LO promoter,
we aimed to identify the HDAC responsible for the TSA effects on
5-LO gene expression.
By the use of subtype-specific HDAC inhibitors, we found that
the HDAC2 and HDAC3 inhibitor apicidin as well as the
HDAC1–HDAC3 inhibitor MS-275 can mimic the TSA effects on 5-
LO mRNA expression and promoter activity whereas the HDAC8
inhibitor SB-379278A and the HDAC class II inhibitor MC-1568
were inactive. Regarding MS-275, the reported IC50-values for
HDAC1 are 180–300 nM whereas those for HDAC2 and HDAC3 are
1.1 M and between 0.7 and 8 M, respectively. Thus, MS-275
preferentially inhibits HDAC1 but can also reduce HDAC2 and
HDAC3 activity at the concentrations required for induction of 
5-LO promoter activity (Table 1). Apicidin, which inhibits HDAC2
and HDAC3 but not HDAC1 also induced 5-LO mRNA expression.
Of note, apicidin was able to achieve similar effects on 5-LO pro-
moter activation and mRNA induction as TSA (Fig. 1A and B).
Taken together, our HDAC inhibitor studies suggest that either
HDAC2 or HDAC3 or both are involved in the regulation of 5-LO
expression. This conclusion was confirmed by knockdown exper-
iments in Mono Mac6 cells. Knockdown of HDAC2 or HDAC3
strongly induced cellular 5-LO mRNA expression, whereas HDAC1
knockdown did not induce 5-LO mRNA expression. The results
suggest that HDAC3 and to a somewhat lesser extend HDAC2 are
involved in the regulation of 5-LO promoter activity. However, one
should consider that we were not able to get an as efficient knock-
down of HDAC2 as with HDAC3. Thus, the slightly lower induction
in 5-LO mRNA expression achieved with the HDAC2 knockdown
could also be at least in part related to the differences in knock-
down efficiency. Of note, addition of the HDAC inhibitor TSA to the
HDAC2 or HDAC3 knockdown cell lines revealed an only weak
additive effect of the drug suggesting that both knockdowns were
efficient (Fig. 3). The data suggest that inhibition of either HDAC2
or HDAC3 is sufficient for 5-LO up-regulation and that the benefit
of combined HDAC2 and HDAC3 inhibition is limited.
Previously, we have shown that HDAC inhibition increases 5-
LO promoter activity by recruitment of Sp1 to the core promoter
[8]. Thus, it seems that HDAC2/3 inhibition is the critical step that
leads to Sp1 recruitment. Interestingly, a similar phenomenon has
been described for the induction of the cdk inhibitor p21 [23].
In this study, we found that the 5-LO mRNA induction by HDAC
inhibition is not restricted to Mono Mac6 cells but can also be
observed in other myeloid cell lines such as HL-60 and U937. Of
interest, the lowest 5-LO mRNA induction by TSA was observed in
U937 cells. In comparison to Mono Mac6 or HL-60 cells, U937
cells show low basal 5-LO expression, due to methylation of the 
5-LO core promoter in these cells [4]. This correlates with the
presence of H3K9me, a marker for transcriptional repression,
which was detectable in U937 but not in Mono Mac6 or HL-60
cells (Fig. 6). DNA methylation is often connected to histone
hypoacetylation [24] and for some genes it was shown that HDAC
inhibitors, such as TSA, are able to demethylate and reactivate
silenced genes [25–27]. In U937 cells, we found that TSA reduces
the H3K9 marker and leads to a strong acetylation of H3, but the
effects of the drug on 5-LO mRNA expression are modest. In HL-
60 and U937 cells but not in Mono Mac6 cells, TSA increased H4
acetylation. H3 and H4 acetylations are considered as markers of
actively transcribed genes. Of note, the turnover of histone acety-
lations is rather fast and the half-life of the histone acetylation
marks is in the range of a few minutes. This fact points to rapid
acetylation/deacetylation cycles where HDAC inhibitors shift the
equilibrium towards the acetylated forms. In HL-60 and Mono
Mac6 cells, the changes in H3 and H4 acetylation by TSA as well
as the time course of the TSA effect does not directly correlate
with the induction of 5-LO mRNA expression. For example, in
Mono Mac6 cells there is almost no effect of TSA on H3 as well as
H4 acetylation (Fig. 5B), whereas 5-LO mRNA is induced up to 62-
fold. On the other hand, a good correlation between up-regulation
of 5-LO mRNA expression and H3K4me3 is observed after HDAC
inhibition in all three cell lines (Figs 4 and 6). In contrast to acety-
lation, histone methylation markers represent rather stable signals
with half-lives in the range of 0.5–1 day and our data suggest that
HDAC inhibition leads to a slow but prominent increase in
H3K4me3 at the 5-LO promoter.
However, at the moment, the precise link between HDAC inhi-
bition and H3K4 trimethylation and the recruitment of Sp1 to the
promoter is unknown. Methylation of H3K4 is catalysed by the
MLL protein family and H3K4 trimethylation by the MLL complex
is stimulated by acetylated histone H3 [15]. This observation pro-
vides a functional link between histone H3 acetylation and H3K4
trimethylation and could thus be responsible for the increase in
H3K4me3 in response to HDAC inhibition. On the other hand,
induction of 5-LO mRNA expression by TSA was partially inhibited
by cycloheximide, which suggests that protein biosynthesis is
required for full up-regulation and that TSA obviously induces the
expression of proteins that are involved in the up-regulation of the
cellular 5-LO mRNA level. Similar observations were made with
TGF- and 1,25(OH)2D3, which induce 5-LO mRNA expression in
myeloid cell lines [5, 6, 28]. There, cycloheximide acted as partial
inhibitor of TGF--induced 5-LO mRNA expression [29, 30].
Another interesting function of HDAC3 is its interference with
the P-TEFb complex. P-TEFb is a heterodimeric complex com-
posed of cyclin-dependent kinase 9 (cdk9) and a regulatory cyclin
subunit of the T family [31, 32]. It is a transcription elongation
factor that enhances transcriptional elongation by phosphorylat-
ing RNA polymerase II at Ser2 of the carboxy-terminal domain.
The kinase activity of P-TEFb is regulated by cdk9 acetylation
where p300 was identified as acetylase and HDAC3 was shown 
to be a pTEFb deacetylase [32]. This observation provides a
mechanistic link between HDAC3 inhibition and the stimulation of
transcript elongation. Interestingly, 5-LO transcript elongation
was found to be a critical step in the regulation of 5-LO mRNA
expression. We showed that the strong induction of 5-LO mRNA
expression by TGF- and 1,25-dihydroxyvitamin D3 is mainly due1472 © 2011 The Authors
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to the stimulation of transcript elongation [5, 6, 28]. Thus, the
prominent up-regulation of 5-LO mRNA expression observed
after pharmacological inhibition of HDAC3 or after HDAC3 knock-
down certainly involves the stimulation of 5-LO promoter activity
as shown by reporter gene assays, but additional effects of
HDAC3 inhibition on 5-LO transcript elongation via P-TEFb acti-
vation could also contribute.
Another interesting observation is that knockdown of HDAC2
leads to a significant increase in 5-LO mRNA expression in Mono
Mac6 cells (Fig. 2). HDAC2 has been shown to be involved in the
suppression of the expression of proinflammatory genes and
reduced HDAC2 expression was observed in alveolar tissue from
patients with chronic obstructive pulmonary disease (COPD)
[33–35]. Because leukotrienes are major players in inflammatory
diseases in the lung such as asthma and COPD and because ele-
vated levels of leukotrienes have been found in COPD patients
[36], our data suggest that it might be of interest to check whether
there is an increased expression of 5-LO in lung tissue of COPD
patients.
Histone deacetylase inhibition has also been linked to cell dif-
ferentiation. The HDAC inhibitor butyrate has been shown to
induce cell differentiation in myeloid cell lines and this effect is
enhanced by the combination with DMSO and hexamethylene
bisacetamide [37]. Butyrate has also been found to induce 5-LO
expression in colorectal carcinoma Caco-2 cells and silencing of
HDAC3 and other class I HDACs in colon cancer cell lines leads to
cell growth inhibition, differentiation and apoptosis [23]. Thus,
regulation of 5-LO promoter activity by HDAC2 and/or HDAC3
seems to link 5-LO expression with cell differentiation.
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